Posts

Astellas Pharma Inc. President and CEO Kenji Yasukawa, Ph.D., today announced the opening of a new late-stage clinical and commercial manufacturing facility in Sanford, N.C. The facility will allow Astellas Pharma to expand the company’s resources and team to establish a robust, global supply chain and expand its therapeutic and geographic scope.

Powered by the company’s blockbuster checkpoint inhibitor Keytruda, Merck is forecasting the potential of more than 80 new regulatory approvals in oncology through 2028.

Bayer is building an oncology powerhouse. The Germany-based biopharma leader is on a mission to become one of the top 10 oncology companies by 2030, and an ambitious mission requires an equally driven leadership team. To that end, Bayer snagged ex-GSK global oncology head Christine Roth to lead the company’s Oncology Strategic Business Unit, then dipped into GSK waters again to bring Tara Frenkl on board as head of oncology development.